Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sophia Genetics Sa (NQ: SOPH )

5.085 -0.015 (-0.29%)
Streaming Delayed Price Updated: 2:52 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sophia Genetics Sa

< Previous 1 2 Next >
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Present at the Barclays 26th Annual Global Healthcare Conference
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS Reports Fourth Quarter and Full Year 2023 Results
Strong momentum to continue in 2024 as SOPHiA GENETICS announces record revenue, 35 new customer additions in Q4, and 36% cash burn decline in FY 2023 
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Participate in Fireside Chat at the 44th Annual TD Cowen Health Care Conference
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Present at the J.P. Morgan 2024 Healthcare Conference
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2023
Record results on growth acceleration, significant improvement in operating loss and cash burn 
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Announce Financial Results for the Third Quarter of Fiscal 2023 on November 7, 2023
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Robust growth and efficient expense execution continues 
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS Reports Financial Results for the First Quarter of Fiscal 2023
Strong growth momentum and efficient expense execution continues 
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS’ SOPHiA DDM™ HRD Solution is Tapped by Unipath Specialty Laboratory Limited
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS Celebrates Swiss Biotech Award
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS to Announce Financial Results for the First Quarter of Fiscal 2023 on May 9, 2023
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
The University of Maryland Medical Center Chooses SOPHiA GENETICS Technology
From SOPHiA GENETICS
Via Business Wire
Krsnaa Diagnostics is Live on SOPHiA GENETICS
From SOPHiA GENETICS
Via Business Wire
Tel Aviv Sourasky Medical Center Chooses SOPHiA DDMTM HRD Solution of SOPHiA GENETICS
From SOPHiA GENETICS
Via Business Wire
Acutis Diagnostics Leverages SOPHiA GENETICS Technology to Create New Next Generation Sequencing Test
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS and Agilent Partner on Comprehensive Solution for Cancer Analysis
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS Reports Fourth Quarter and Year End 2022 Financial Results
From SOPHiA GENETICS SA
Via Business Wire
University of Arkansas for Medical Sciences Will Use SOPHiA GENETICS to Advance Clinical Research for Blood Cancers
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2023
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation Sequencing
From SOPHiA GENETICS
Via Business Wire
Synergy Laboratories Taps SOPHiA GENETICS Technology for New Cancer Profiling Solution
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full Year of Fiscal 2022 on March 7, 2023
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS Expands Partnership With AstraZeneca to Include Multimodal Approaches for Cancer Drug Development
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS and Leading US Cancer Center Collaborate to Combine Cancer Analysis Technology for Liquid Biopsies
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS to Present at the J.P. Morgan 2023 Healthcare Conference
From SOPHiA GENETICS
Via Business Wire
SOPHiA GENETICS Reports Financial Results for the Third Quarter of Fiscal 2022
Sustainable growth momentum evident despite foreign exchange headwinds 
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
SOPHiA GENETICS to Participate in Upcoming November Investor Conferences
From SOPHiA GENETICS, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.